Abstract

Objectives: Novel biomarkers to predict future risk of coronary artery disease, especially in the early stage, are warranted. The goal of this study was to determine whether SFRP5, a novel anti-inflammatory adipokine, is associated with future cardiovascular events.
Methods: This is a 4-year follow-up study that included 81 subjects with CAG (+) and 87 subjects with CAG (-). SFRP5 levels was analyzed by ELISA. 2-year and 4-year follow-up were conducted for the occurrence of major adverse cardiac events (MACE), including unstable angina pectoris, ischemic stroke, nonfatal myocardial infarction, revascularization, and cardiovascular death.
Results: In multivariate Cox regression analysis, high SFRP5 significantly predicted patients’ MACE with an HR of 2.174 (95% CI 1.169, 4.041; p=0.014) at 2-year follow-up, and with an HR of 1.974 (95% CI 1.138, 3.426; p=0.016) at 4-year follow-up respectively. The incidence of MACE was significantly increased in the high SFRP5 group for CAG(-) patients ((HR (95%CI) 3.326(1.275, 8.680), p=0.014 for 2-year; HR (95%CI) 2.590(1.122, 5.978), p=0.026) for 4-year), as well as for patients over 65 years (HR(95%CI) 4.931(1.989, 12.222), p<0.001 for 2-year; HR(95%CI) 3.194(1.541, 6.621), p=0.002 for 4-year, respectively).
Conclusion: A high serum concentration of SFRP5 is associated with the occurrence of future CV events,especially in the elderly.

Keywords: SFRP5; Coronaryarterydisease; Cardiovascularevent; Angiography; Hypertension; Inflammation